Mechanism-Based Inhibition: Deriving KI and kinact Directly from Time-Dependent IC50 Values

被引:110
作者
Krippendorff, Ben-Fillippo [1 ,2 ]
Neuhaus, Roland [3 ]
Lienau, Philip [3 ]
Reichel, Andreas [3 ]
Huisinga, Wilhelm [1 ,2 ]
机构
[1] Natl Univ Ireland Maynooth, Hamilton Inst, Maynooth, Kildare, Ireland
[2] Int Max Planck Res Sch Computat Biol & Sci Comp, Berlin, Germany
[3] Bayer Schering Pharma AG, Dept Res Pharmacokinet, Berlin, Germany
关键词
irreversible inhibition; time-dependent IC50 values; Cheng-Prusoff relation; DRUG-DRUG INTERACTIONS; HUMAN CYTOCHROME-P450 ENZYMES; HUMAN LIVER-MICROSOMES; CYP INHIBITION; MASS-SPECTROMETRY; GRAPEFRUIT JUICE; VITRO; INACTIVATION; DISCOVERY; 3A4;
D O I
10.1177/1087057109336751
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The potential of enzyme inhibition of a drug is frequency quantified in terms of IC50 values. Although this is a suitable quantity for reversible inhibitors, concerns arise when dealing with irreversible or mechanism-based inhibitors (MBIs). IC50 values of MBIs are time dependent, causing serious problems when aiming at ranking different compounds with respect to their inhibitory potential. As a consequence, Most studies and ranking schemes related to MBIs rely oil the inhibition constant (K-I) and the rate of enzyme inactivation (k(inact)) rather than on IC50 values. In this article, the authors derive a novel relation between potentially time-dependent IC50 values and K-I, k(inact) parameters for different types of inhibition. This allows for direct estimation of K-I and k(inact), values from time-dependent IC50 values, even without the need of additional preincubation experiments. The application of this approach is illustrated Using a fluorimetric assay to access the drug-drug interaction potential associated with new chemical entities. The approach call easily be implemented Using standard software tools (e.g., XLfit) and may also be suitable for applications where mechanism-based inhibition is a desired mode of action (e.g., at particular pharmacological drug targets). (Journal of Biomolecular Screening 2009:913-923)
引用
收藏
页码:913 / 923
页数:11
相关论文
共 39 条
[1]   Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis [J].
Atkinson, A ;
Kenny, JR ;
Grime, K .
DRUG METABOLISM AND DISPOSITION, 2005, 33 (11) :1637-1647
[2]   Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug drug interactions: Pitfalls, progress and promise [J].
Bachmann, KA .
CURRENT DRUG METABOLISM, 2006, 7 (01) :1-14
[3]   Evaluation of fluorescence- and mass spectrometry - Based CYP inhibition assays for use in drug discovery [J].
Bell, Leslie ;
Bickford, Shari ;
Nguyen, Phong Hung ;
Wang, Jianling ;
He, Timothy ;
Zhang, Bailin ;
Friche, Yannick ;
Zimmerlin, Alfred ;
Urban, Laszlo ;
Bojanic, Dejan .
JOURNAL OF BIOMOLECULAR SCREENING, 2008, 13 (05) :343-353
[4]  
Berry Loren M, 2008, Drug Metab Lett, V2, P51, DOI 10.2174/187231208783478407
[5]   Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: Comparison with fluoxetine and quinidine [J].
Bertelsen, KM ;
Venkatakrishnan, K ;
Von Moltke, LL ;
Obach, RS ;
Greenblatt, DJ .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (03) :289-293
[6]   Targeting cytochrome P450 enzymes: A new approach in anti-cancer drug development [J].
Bruno, Robert D. ;
Njar, Vincent C. O. .
BIOORGANIC & MEDICINAL CHEMISTRY, 2007, 15 (15) :5047-5060
[7]   Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4 [J].
Chan, WK ;
Delucchi, AB .
LIFE SCIENCES, 2000, 67 (25) :3103-3112
[8]   Cytochrome P450 3A4-mediated bioactivation of raloxifene: Irreversible enzyme inhibition and thiol adduct formation [J].
Chen, Q ;
Ngui, JS ;
Doss, GA ;
Wang, RW ;
Cai, XX ;
DiNinno, FP ;
Blizzard, TA ;
Hammond, ML ;
Stearns, RA ;
Evans, DC ;
Baillie, TA ;
Tang, W .
CHEMICAL RESEARCH IN TOXICOLOGY, 2002, 15 (07) :907-914
[9]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[10]   CHARACTERIZATION OF THE INHIBITION OF P4501A2 BY FURAFYLLINE [J].
CLARKE, SE ;
AYRTON, AD ;
CHENERY, RJ .
XENOBIOTICA, 1994, 24 (06) :517-526